The $471 Billion Question: What's next for employers on the GLP-1 rollercoaster?

Join Bradley Nelson and Tom Davies for the latest episode of Pharmland as they tackle the $471 billion question – what’s driving the GLP-1 craze in 2025? From new approvals for chronic kidney disease and certain cardiovascular conditions to potential further expanded indications for conditions like non-alcoholic steatohepatitis (NASH) and Alzheimer’s, learn how these revolutionary drugs are reshaping the pharmaceutical market, what they mean for the future of innovation, and the potential impact on plan sponsors and patients.